Form 4: Jazz Pharmaceuticals SVP, Technical Operations, Mary Elizabeth Henderson, Reports Stock Transactions

Mary Elizabeth Henderson, SVP, Technical Operations at Jazz Pharmaceuticals, reports the acquisition of 5,178 ordinary shares and disposal of 15,941 ordinary shares on March 1, 2024.

Summary

• On March 1, 2024, Mary Elizabeth Henderson, SVP, Technical Operations at Jazz Pharmaceuticals, reported transactions involving the company's ordinary shares.
• Henderson acquired 5,178 ordinary shares at a price of $0.0.
• Henderson disposed of 15,941 ordinary shares.
• Following these transactions, the total number of shares beneficially owned by Henderson is not explicitly stated in the provided document.
• The reported transactions also include the grant of restricted stock units under the company's 2011 Equity Incentive Plan, which vest in equal annual installments over four years starting March 5, 2024.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by a company insider. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Positives

• The grant of restricted stock units to Henderson aligns her interests with the long-term performance of Jazz Pharmaceuticals.

Future Outlook

The vesting schedule of the restricted stock units suggests a continued alignment of Henderson's interests with the company's performance over the next four years.

Industry Context

Form 4 filings are a routine part of regulatory compliance for corporate insiders and provide transparency into their transactions in company stock. These filings are closely watched by investors seeking insights into management's perspective on the company's value and future prospects.

Comparison to Industry Standards

• Stock-based compensation is a common practice in the pharmaceutical industry to incentivize executives and align their interests with shareholders.
• Vesting schedules, like the four-year schedule described in the document, are standard in equity compensation plans to encourage long-term commitment.
• Comparing Henderson's stock transactions and equity grants to those of executives at comparable companies like Amgen, Gilead Sciences, or Biogen would provide a benchmark for assessing the magnitude and structure of her compensation.

Stakeholder Impact

• The stock transactions by a company insider can influence investor sentiment and potentially impact the stock price.
• The granting of restricted stock units can motivate the executive to improve company performance, benefiting shareholders.

Key Dates